Abstract: Dosage forms and methods for the controlled release of antidepressives, such as exemplified by phenoxyethyl substituted-1,2,4-triazolones, as a suspension or a slurry over a prolonged period of time are described.

Abstract: A wound-covering agent containing a polymer having a group represented by formula (I) (wherein R1, R2 and R3 are the same or different and each represents hydrogen atom or C1-4 alkyl, and m is an integer of 2 to 4); a wound-covering material containing the preparation; and a method of wound healing which comprises the step of covering the wound of a subject with the wound-covering material to protect the wound.

Abstract: Described is a fragrance control release system which is an emulsifier-free, single phase, nonporous, continuous, permeable polymeric film having a substantially uniform thickness of from about 1 up to about 150 microns, having entrapped and dissolved therein molecules of at least one fragrance substance capable of evolving from said film into the environment proximate said film by means of molecular diffusion at a permeation rate of from about 1×10−7 up to about 0.1 mg-mm/cm2-min in a sustained and controlled release manner. Also described is a process for using the aforementioned system for imparting a fragrance into the environment above the unobstructed outer surface of the aforementioned polymer film which is coated on the surface of a solid or semi-solid support, e.g., a woven or non-woven fabric substrate; or a solid surface or human epidermis.

Abstract: Compositions and methods are provided for forming tissue-adherent hydrogels using substantially dry precursors. The dehydrated precursors are premixed prior to in situ therapy and utilize naturally-occurring body fluids as an aqueous environment that initiates transformation, which causes dissolution and nearly simultaneous crosslinking of the precursors, thus forming an insoluble hydrogel implant. The dehydrated precursor-based hydrogels may be used as sealants for fluid leaks from tissue, as adherent drug delivery depots, as means for augmenting and/or supporting tissue, and as means for serving a variety of other useful medical and surgical purposes.

Abstract: The invention provides an ophthalmic aqueous composition for topical administration, comprising: (a) a block copolymer of propylene oxide and ethylene oxide in concentration sufficient to provide viscosity of less than about 25 centipoise at ambient temperature and viscosity of from about 25 to about 55 centipoise when applied topically to a patient; (b) hydroxypropyl methylcellulose in concentration sufficient to improve the durability of the gel formed by the block copolymer. The invention further provides a method for administering ophthalmic pharmaceuticals.

Abstract: The present invention provides methods of increasing the biological activity of a bioactive agent by complexing the bioactive agent with a complexing agent. In one preferred embodiment, the bioactive agent is an antibiotic and the complexing agent is a cyclodextrin. However, the invention may be extended to include any drugs as bioactive agents. In certain preferred embodiments, the bioactive agent fits into a hydrophobic core of a complexing agent.

Abstract: Methods for inducing a thermoplastic polymer, which can be non-mesogenic, to exhibit liquid crystalline properties have been developed. The method includes the steps of (a) heating the polymer from an initial temperature below its glass transition temperature (Tg) to a temperature greater than its Tg and below its melting temperature (Tm); (b) exposing the polymer to a pressure greater than about 2 metric tons/in2, preferably between about 2 and 10 metric tons/in2, preferably for at least about one minute, while maintaining the temperature greater than its Tg; and (c) cooling the polymer below the Tg while maintaining the elevated pressure. Unlike many prior art transition processes which are reversible, this process provides a liquid crystal state that can be maintained for years at ambient conditions. In a preferred embodiment, the plastics are bioerodible thermoplastic polymers, such as polyanhydrides, some polyesters, polyamides, and polyaromatics.

Abstract: The present invention relates to purified platinum complexes in which platinum is coordinated to form a single N,O- or O,O-chelate of an amidomalonate. The chelates, and pharmaceutically acceptable formulations thereof, are useful for the treatment of cancer. The platinum chelates may additionally be linked to one or more functional groups which increases water solubility and/or assists in tumor targeting of the chelate. Examples of tumor targeting moieties include polymers, in which one or more platinum chelates are attached to the polymer backbone via linkers capable of being cleaved in the body, and molecules with a high affinity for receptors which are concentrated or upregulated in tumor tissue and/or the tumor vasculature.

Abstract: The present invention provides a method/system for remote and local controlled delivery of pharmaceutical compounds or biomolecule collection using electromagnetic energy. Controlled electromagnetic energy driven systems are integrated into patches and other delivery devices. Also provided is a drug delivery or biomolecule collection patch electronically monitored by global positioning system.

Abstract: A care or make-up composition for keratin substances such as the skin, the lips or superficial body growths, this composition containing fibers and particles of an at least partially crosslinked solid elastomeric polyorganosiloxane suspended in an aqueous phase, giving a homogeneous deposit on these keratin substances, while at the same time providing softness and a sensation of freshness; methods of using the composition; and methods of making the composition.

Abstract: Disclosed is a process for producing powders from high viscosity fluids including mixing a mixture comprising a high viscosity fluid and at least one absorbing agent until a dry dispersion is produced; combining, under shear, a combination of the dry dispersion with a naturally derived oil having a melting point at least about 110° F.; and granulating the combination into a powder. Also disclosed are pharmaceutical compositions that include a high viscosity fluid, at least one absorbing agent; and a naturally derived oil with a melting point at least about 110° F., together with sustained-release embodiments of such compositions.

Abstract: New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3′diindolylmethane (LTR-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia and endometriosis.

Abstract: Chromium is an essential element which has been shown to have beneficial effects on carbohydrate and lipid metabolism. Often, dietary intake is suboptimal, and nutritional supplements may not be effective due to poor absorption in the gastrointestinal tract. A novel chromium-histidine complex has been prepared which significantly improves absorption capability over current available chromium nutritional supplements. The complex is safe, easily prepared and may be combined with an ingestible carrier for consumption as a tablet, capsule, aqueous solution, food or food product.

Abstract: A method for preparing cross-linked collagen and cross-linked collagen products. The method includes incubating collagen in a solution including water, at least one polar solvent and at least one sugar, to form cross-linked collagen. The solution may include a buffer having a suitable pH and ionic strength. The method may include removing excess unreacted sugar(s) and polar solvent(s) by washing the cross-linked collagen or by other methods. The method may also include dehydrating the cross-linked collagen, and may include subjecting the cross-linked collagen to critical point drying, or subjecting the collagen to drying or freeze-drying prior to cross-linking. The collagen may be prepared from atelopeptide collagen to reduce antigenicity, but may also be prepared from other suitable collagen types. The concentration and type of the polar solvent(s), the concentration and type of the reducing sugar(s), and the incubation duration may be varied to control the degree of cross-linking.

Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.

Abstract: The invention provides NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates, in which the N2O2− functional group is bonded to a carbon atom. The invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The invention further provides a method of preparing NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates.

Abstract: Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible polymer for pulmonary sustained drug release applications. Also provided are packaged products including drug-containing powder in a container that is receivable by and operable with a dry powder inhaler to produce an aerosol including dispersed drug-containing particles when the inhaler is actuated.

Abstract: A polymeric construct is disclosed. The construct comprises a biodegradable ABA block copolymer having a selected medicament associated therewith. The medicament thus present is provided in a slow release form.

Abstract: The present invention relates to a new makeup kit comprising a first, goniochromatic pigment composition which is intended to form a base layer and a second, conventional pigment composition having one of the colors of the first pigment, the second composition being intended to form a surface layer comprising decorative motifs. Depending on the viewing angle, therefore, it is possible to see the said motifs appear or disappear. This kit is intended in particular for making up the nails, lips, cheeks or eyelids, or else the body. The invention also relates to a method of making up the human face, lips or body.

Abstract: The invention concerns an oxidising aqueous composition useful in particular for disinfection, hygiene and depollution purposes, and for surface treatment (particularly a metal surface to be stripped and/or passivated), and said composition, containing in water hydrogen peroxide, a RCO2H/RCO3H mixture (wherein R is a C1-C6 aliphatic radical with linear or branched hydrocarbon chain, saturated or unsaturated), a stabilising agent which is an acid and, as the case may be, Ag+ ions. The invention is characterised in that it contains ions of at least one metal M which are ions of AgII, AgIII, VV, NbV, TaV, MoVI, WVI, CoIII, InIII or TlIII. Advantageously, said composition can be in gel form. The invention also concerns the method for preparing said composition.